Associated Papers
Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer.
Corvigno S et al.
Frontiers in Oncology, 2025
40365343 (PubMed )
Supplement: Table6.xlsx › a
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma.
Villa M et al.
British Journal of Cancer, 2024
39478125 (PubMed )
Supplement: 41416_2024_2881_MOESM1_ESM.pdf
Evolutionary history of adenomas to colorectal cancer in FAP families.
Yang C et al.
Frontiers in Genetics, 2024
39021676 (PubMed )
Supplement: DataSheet1.ZIP › Somatic › 18R10487.xls › SNVIndel
Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune microenvironment.
Tang S et al.
National Science Review, 2023
37051524 (PubMed )
Supplement: nwad028_supplemental_files.zip › Table_S2.xlsx › Mutations_in_93_WGS_samples
Establishment and Characterization of a Novel Human Ocular Adnexal Sebaceous Carcinoma Cell Line.
Rong AJ et al.
Translational Vision Science & Technology, 2021
34043754 (PubMed )
Supplement: tvst-10-6-34_s001.xlsx › 50_tum_norm_mutect.vcf.anno.hg3
A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade.
Lazdun Y et al.
Molecular Cancer Research : Mcr, 2021
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.
Fontana D et al.
Hemasphere, 2020
33196013 (PubMed )
Supplement: hs9-4-e497-s006.xlsx › Sheet1
Mutational heterogeneity in non-serous ovarian cancers.
Teer JK et al.
Scientific Reports, 2017
28852190 (PubMed )
Supplement: 41598_2017_10432_MOESM2_ESM.xlsx › Supp_Table_11
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › M121224
Select a paper to view details